Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a buy rating and issued a $9.00 price objective on shares of Trevena in a research note on Tuesday, April 2nd.

Trevena Stock Performance

NASDAQ TRVN opened at $0.40 on Friday. The company has a current ratio of 4.66, a quick ratio of 4.66 and a debt-to-equity ratio of 8.35. The firm has a market capitalization of $7.30 million, a price-to-earnings ratio of -0.13 and a beta of 1.10. The firm’s 50 day simple moving average is $0.51 and its 200 day simple moving average is $0.58. Trevena has a 1 year low of $0.30 and a 1 year high of $3.28.

Hedge Funds Weigh In On Trevena

Large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP bought a new position in shares of Trevena during the fourth quarter valued at $40,000. Jump Financial LLC bought a new position in Trevena during the third quarter worth $27,000. Jane Street Group LLC raised its stake in Trevena by 166.2% during the first quarter. Jane Street Group LLC now owns 45,330 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 28,303 shares during the last quarter. Renaissance Technologies LLC raised its stake in Trevena by 51.8% during the first quarter. Renaissance Technologies LLC now owns 70,532 shares of the biopharmaceutical company’s stock worth $49,000 after buying an additional 24,080 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Trevena during the second quarter worth $70,000. Institutional investors own 13.56% of the company’s stock.

About Trevena

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.